For a long time, the biology of Dupuytren’s contracture has remained a mystery. This has made the race for a cure much harder than people had previously anticipated.
The cellular components involved in the pathogenesis of Dupuytren’s contracture include changes in growth factors, disturbed protein expression of the cytokine cells, alterations in genes as well as a change in the components of the extracellular.
On the other hand, the histology of Dupuytren’s contracture shows a varying increase in the levels of collagen type I and II, myoglobin protein in the tissues of the palm.
These varying levels trigger the appearance of nodules in the palm. These nodules then slowly progress into a more prominent cord that ‘pulls’ the fingers inwards.
The information available on the biology of Dupuytren’s contracture is valuable, yet the overall etiology of the disease remains unknown.
The risk factors of the disease are just as vague. This makes it impossible for scientists and researchers to look for a definite cure that can eliminate the disease forever.
Thanks to constant research and analysis, scientists have now been able to pinpoint the exact cells that are responsible for the progression or aggravation of Dupuytren’s contracture.
Recent studies found that a specific drug that goes by the name of ‘adalimumab’ may actually help in the elimination of the cells that cause Dupuytren’s contracture to progress.
Scientists were able to find that out after realizing Tumor Necrosis Factor (NTF) is actually what causes the abnormal development of myofibroblast cells. These cells are responsible for the formation of nodules in the palmar fascia of those affected by Dupuytren’s contracture.
The drug acts as an anti-TNF agent and works on presenting the formation of such nodules.
A professor at the University of Oxford has proposed the initiation of clinical trials to see whether or not the drug is a promising cure for those suffering from the hand-mobilizing disease.
Here’s the proposal:
The anti-TNF drug or Adalimumab would be injected into the developing nodules present in the palmar fascia of those affected by Dupuytren’s contracture.
The main job of this drug would be to inhibit or pause the growth of nodules, thus preventing the disease from progressing even further. However, we aren’t yet sure how effective or safe this option is.
It is still not available as a for-sure treatment of Dupuytren’s contracture. Until then, you can use creams as they’re safe and reliable.
Comments will be approved before showing up.